Disposition, metabolism and mass balance of [ 14C]apremilast following oral administration

Xenobiotica

Volumn 41, Issue 12, 2011, Pages 1063-1075

  Hoffmann, Matthew ^a   Kumar, Gondi ^a   Schafer, Peter ^b   Cedzik, Dorota ^b   Capone, Lori ^b   Fong, Kei Lai ^c   Gu, Zheming ^d   Heller, Dennis ^d   Feng, Hao ^d   Surapaneni, Sekhar ^a   Laskin, Oscar ^e   Wu, Anfan ^f  

^a Drug Metabolism and Pharmacokinetics Department   (United States)

^b Translational Development Department   (United States)

^c Accellient Partners LLC   (United States)

^d XENOBIOTIC LABORATORIES INC   (United States)

^e R2D Pharma Services LLC   (United States)

^f Exploratory Clinical Pharmacology Department   (United States)

Author keywords

Apremilast; Human; Metabolism; Phosphodiesterase type 4; Tumour necrosis factor

Indexed keywords

APREMILAST; APREMILAST C 14; DRUG METABOLITE; O DESMETHYL APREMILAST GLUCURONIDE; PHOSPHODIESTERASE IV; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RADIOACTIVITY;

ADMINISTRATION, ORAL; ADULT; CARBON RADIOISOTOPES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PHOSPHODIESTERASE 4 INHIBITORS; RADIOACTIVITY; THALIDOMIDE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 80655145912     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.604745     Document Type: Article

References (8)

1. Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C. (2008). An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-infammatory agent, apremilast. Curr Med Res Opin 24:1529-1538. (Pubitemid 351741586)
2. Kodimuthali A, Jabaris SSL, Pal M. (2008). Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.;J Med Chem; 51:5471-5489.
3. Man HW, Schafer P, Wong LM, Patterson RT, Corral LG, Raymon H, Blease K, Leisten J, Shirley MA, Tang Y, Babusis DM, Chen R, Stirling D, Muller GW. (2009). Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2- methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem 52:1522-1524.
4. McHugh SM, Rowland TL. (1997). Talidomide and derivatives: immunological investigations of tumour necrosis factor-α (TNF-α) inhibition suggest drugs capable of selective gene regulation. Clin Exp Immunol 110:151-154. (Pubitemid 27469584)
5. Papp K, Bolduc C, Rohane P, Sutherland D, Jones M, Hu A, Zeldis J, Taci D, Kaufmann R. (2008). A phase 2 study demonstrating the efcacy and safety of the oral therapy CC-10004 in subjects with moderate to severe psoriasis [abstract]. J Amer Acad Dermatol 58, AB3.
6. Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, Bartlett JB, Loveland MA, Gilhar A, Cheung YF, Baillie GS, Houslay MD, Man HW, Muller GW, Stirling DI.(2010). Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-infammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 159:842-855.
7. Van der Mey M, Hatzelmann A, Van Klink GP, Van der Laan IJ, Sterk GJ, Tibaut U, Ulrich WR, Timmerman H. (2001). Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra-and cis-hexahydrophthalazinones. J Med Chem 44:2523-2535. (Pubitemid 32852142)
8. Wu A, Rohane P, Patin J, Laskin O. (2006). Efects of ketoconazole on the pharmacokinetics of CC10004 in health subjects [abstract]. J Clin Pharm: ACCP Annual Meeting Proceedings, 46:1095.